Every 10-Q that Exelixis Inc (EXEL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EXEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXEL filings page.
Exelixis, Inc. reported higher results for the quarter ended June 30, 2026. Total revenues rose to $628.7 million from $568.3 million a year earlier, driven mainly by CABOMETYX and other cabozantinib sales, with net product revenues of $573.0 million. Net income increased to $212.1 million, or $0.82 diluted EPS, versus $184.8 million, or $0.65. For the first half of 2026, revenues reached $1.24 billion and net income $422.5 million.
The company generated $559.6 million of operating cash flow in the first six months and ended June with $1.38 billion in cash, cash equivalents and marketable securities, after spending $753.3 million on share repurchases under its authorizations. Exelixis highlights progress for lead asset zanzalintinib, including an FDA NDA under review for metastatic colorectal cancer with a December 3, 2026 PDUFA date and multiple ongoing pivotal and phase 2 studies across tumor types. The company also describes extensive patent litigation and evolving U.S. pricing rules that could affect future CABOMETYX revenues.
Exelixis, Inc. reported strong first‑quarter 2026 growth, driven mainly by its cabozantinib franchise. Total revenues rose to $610.8 million from $555.4 million a year earlier, with net product revenues increasing to $555.0 million. Net income climbed to $210.5 million, up from $159.6 million, and diluted EPS improved to $0.79 from $0.55, reflecting operating leverage as total operating expenses stayed roughly flat.
The company ended the quarter with $1.43 billion in cash, cash equivalents and marketable securities and continued returning capital to shareholders, repurchasing common stock for $430.4 million of cash in the quarter as part of a broader buyback program. Exelixis also highlighted progress in its oncology pipeline, including zanzalintinib, which has an FDA‑accepted New Drug Application in metastatic colorectal cancer and multiple ongoing pivotal and phase 2 studies across several tumor types.
Exelixis reported stronger Q3 results, with total revenues of $597.8M versus $539.5M a year ago. Net product revenues rose to $542.9M, led by CABOMETYX at $539.9M, while collaboration revenues were $54.8M. Operating expenses declined year over year, reflecting the absence of last year’s impairment, and income from operations increased to $236.5M. Net income was $193.6M (diluted EPS $0.69) compared to $118.0M (diluted EPS $0.40) in Q3 2024.
For the first nine months, revenues reached $1.72B and net income was $538.0M. Cash, cash equivalents and marketable securities totaled $1.57B as of September 30, 2025. The company repurchased 24.1 million shares for an aggregate $895.3M under its 2024–2025 programs, with $104.7M remaining available as of September 30, 2025. Shares outstanding were 268,098,000 at September 30, 2025, and 268,112,157 as of October 27, 2025.